Trials Sponsors Conditions Drugs Pricing

Conditions

Renal Cancer Surgery

Outcome Measures

Primary Outcomes (1)

CD 16
NK cells expression of CD16 receptor
postoperative day 1

Secondary Outcomes (8)

CD45
Baseline, end of surgery, postoperative days 1, 3-4, 7
CD3
Baseline, end of surgery, postoperative days 1, 3-4, 7
CD19
Baseline, end of surgery, postoperative days 1, 3-4, 7
CD4
Baseline, end of surgery, postoperative days 1, 3-4, 7
CD8
Baseline, end of surgery, postoperative days 1, 3-4, 7
+3 more secondary outcomes

Study Arms (2)

total intravenous anesthesia

EXPERIMENTAL

Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and propofol for perioperative anesthesia

Drug: PropofolProcedure: Epidural block

Volatile anesthesia

ACTIVE COMPARATOR

Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and sevoflurane for perioperative anesthesia

Drug: SevofluraneProcedure: Epidural block

Interventions

PropofolDrug

Propofol will be used for anesthesia during surgery

total intravenous anesthesia

SevofluraneDrug

Sevoflurane will be used for anesthesia during surgery

Volatile anesthesia

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Surgery for renal cancer
Signed informed concent

You may not qualify if:

Sponsors & Collaborators

Meshalkin Research Institute of Pathology of Circulation
Research networklead

Study Sites (1)

State Research Institute of Circulation Pathology

Novosibirsk, Russia

MeSH Terms

Conditions

Kidney Neoplasms

Interventions

PropofolSevofluraneAnesthesia, Epidural

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Enrollment

20 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: NONE
Purpose: BASIC SCIENCE
Intervention Model: PARALLEL
Sponsor Type: NETWORK
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal investigator

Study Record Dates

First Submitted

April 13, 2018

First Posted

May 2, 2018

Study Start

May 14, 2018

Actual (reported)

Effects of Anesthesia on Immunity in Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Study Arms (2)

total intravenous anesthesia

Volatile anesthesia

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Study Arms (2)

total intravenous anesthesia

Volatile anesthesia

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations